BHVN - NYSE
Biohaven Ltd.
$10.81
+6.7%Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on development of therapies for neurological and immunoscience diseases that can change current treatment paradigms.
At a Glance
Live Snapshotbhvn
Total Assets
Last Annual Value
451.45M
3-Year CAGR
-12%
5-Year CAGR
32%
10-Year CAGR
12%
Biohaven Ltd. Competitors Analysis of Total Assets
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Biohaven Ltd. NYSE:BHVN | 451.45M | -4.2% | 26.0% | N/A | |
 Intellia Therapeutics, Inc. NASDAQ:NTLA | 842.13M | -13.5% | -8.2% | 10.9% | |
 Immunome, Inc. NASDAQ:IMNM | 683.19M | 66.3% | 63.8% | N/A | |
 Vera Therapeutics, Inc. NASDAQ:VERA | 734.73M | 61.2% | 54.4% | N/A | |
 Sionna Therapeutics, Inc. NASDAQ:SION | 325.95M | 84.4% | N/A | N/A | |
 Zenas BioPharma, Inc. NASDAQ:ZBIO | 383.64M | 77.9% | N/A | N/A | |
 Xeris Biopharma Holdings, Inc. NASDAQ:XERS | 383.53M | 5.9% | 4.7% | 27.6% | |
 Celldex Therapeutics, Inc. NASDAQ:CLDX | 582.98M | 7.8% | 5.6% | 4.3% |
Biohaven Ltd. Fair Value Envelope
Related Guides
Continue your BHVN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.